Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
1.420
-0.070 (-4.70%)
At close: Nov 13, 2026, 4:00 PM EST
1.460
+0.040 (2.82%)
After-hours: Nov 13, 2026, 5:14 PM EST
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,910,600
Market Cap
4.68M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Sep 30, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| AIM ImmunoTech | 21 |
| SeaStar Medical Holding | 18 |
| NuCana | 12 |
| CNS Pharmaceuticals | 8 |
| Traws Pharma | 7 |
| Cadrenal Therapeutics | 5 |
| Acurx Pharmaceuticals | 4 |
CANF News
- 22 hours ago - Can-Fite’s Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study - Nasdaq
- 1 day ago - Can-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical Study - Nasdaq
- 1 day ago - Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal - GlobeNewsWire
- 4 days ago - Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment Study - Nasdaq
- 4 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - Nasdaq
- 4 days ago - Can-Fite BioPharma Namodenoson patient reaches 10-year survival in liver cancer - TheFly
- 4 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - GlobeNewsWire
- 7 days ago - Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones - GlobeNewsWire